EUR 1.24
(2.15%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 4.17 Million EUR | 27.17% |
2022 | 4.74 Million EUR | -23.6% |
2021 | 6.21 Million EUR | 109.27% |
2020 | 2.96 Million EUR | 17.59% |
2019 | 2.52 Million EUR | -65.07% |
2018 | 7.22 Million EUR | 8.87% |
2017 | 6.63 Million EUR | -72.39% |
2016 | 24.03 Million EUR | 55.33% |
2015 | 15.47 Million EUR | 154.97% |
2014 | 6.06 Million EUR | -38.12% |
2013 | 9.8 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.86 Million EUR | 0.0% |
2023 Q4 | 972 Thousand EUR | 0.0% |
2023 FY | 6.03 Million EUR | 27.17% |
2023 Q1 | 1.11 Million EUR | -60.85% |
2023 Q2 | 2.89 Million EUR | 159.2% |
2023 Q3 | 972 Thousand EUR | -66.41% |
2022 Q3 | 1.07 Million EUR | -66.8% |
2022 Q2 | 3.23 Million EUR | 145.58% |
2022 Q1 | 1.31 Million EUR | -73.22% |
2022 Q4 | 2.85 Million EUR | 165.3% |
2022 FY | 4.74 Million EUR | -23.6% |
2021 Q2 | 2.98 Million EUR | 131.87% |
2021 Q3 | 1.75 Million EUR | -41.27% |
2021 Q4 | 4.92 Million EUR | 180.99% |
2021 FY | 6.21 Million EUR | 109.27% |
2021 Q1 | 1.28 Million EUR | -45.21% |
2020 FY | 2.96 Million EUR | 17.59% |
2020 Q4 | 2.34 Million EUR | 383.63% |
2020 Q3 | 485.5 Thousand EUR | -58.04% |
2020 Q2 | 1.15 Million EUR | 138.56% |
2020 Q1 | 485 Thousand EUR | -60.76% |
2019 FY | 2.52 Million EUR | -65.07% |
2019 Q1 | 1.55 Million EUR | -17.36% |
2019 Q4 | 1.23 Million EUR | 128.68% |
2019 Q2 | 1.79 Million EUR | 14.82% |
2019 Q3 | 540.5 Thousand EUR | -69.8% |
2018 Q2 | 1.45 Million EUR | 0.0% |
2018 Q1 | 1.45 Million EUR | -33.22% |
2018 FY | 7.22 Million EUR | 8.87% |
2018 Q4 | 1.88 Million EUR | 0.0% |
2018 Q3 | 1.88 Million EUR | 29.61% |
2017 FY | 6.63 Million EUR | -72.39% |
2017 Q3 | 2.17 Million EUR | 454.58% |
2017 Q4 | 2.17 Million EUR | 0.0% |
2017 Q1 | 392.99 Thousand EUR | -92.04% |
2017 Q2 | 392.99 Thousand EUR | 0.0% |
2016 Q2 | 7.09 Million EUR | 0.0% |
2016 Q4 | 4.93 Million EUR | 0.0% |
2016 Q3 | 4.93 Million EUR | -30.41% |
2016 Q1 | 7.09 Million EUR | 54.3% |
2016 FY | 24.03 Million EUR | 55.33% |
2015 FY | 15.47 Million EUR | 154.97% |
2015 Q1 | 3.31 Million EUR | 146.16% |
2015 Q3 | 4.59 Million EUR | 38.6% |
2015 Q2 | 3.31 Million EUR | 0.0% |
2015 Q4 | 4.59 Million EUR | 0.0% |
2014 Q1 | 1.61 Million EUR | 0.0% |
2014 Q3 | 1.34 Million EUR | -16.38% |
2014 FY | 6.06 Million EUR | -38.12% |
2014 Q4 | 1.34 Million EUR | 0.0% |
2014 Q2 | 1.61 Million EUR | 0.0% |
2013 FY | 9.8 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIVAX Société Anonyme | 127.37 Million EUR | 96.721% |
Adocia SA | 15.62 Million EUR | 73.274% |
Aelis Farma SA | 18.81 Million EUR | 77.804% |
Biophytis S.A. | 14.33 Million EUR | 70.857% |
Advicenne S.A. | 8.21 Million EUR | 49.154% |
genOway Société anonyme | 16.73 Million EUR | 75.045% |
IntegraGen SA | 5.35 Million EUR | 21.962% |
Medesis Pharma S.A. | 1.56 Million EUR | -166.974% |
Neovacs S.A. | 10.34 Million EUR | 59.617% |
NFL Biosciences SA | 4.37 Million EUR | 4.512% |
Plant Advanced Technologies SA | 2.76 Million EUR | -51.075% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -143.136% |
Sensorion SA | 27.05 Million EUR | 84.56% |
Theranexus Société Anonyme | 3 Million EUR | -39.002% |
TME Pharma N.V. | 5.49 Million EUR | 24.013% |
Valbiotis SA | 9.86 Million EUR | 57.676% |
TheraVet SA | 1.64 Million EUR | -154.027% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 79.444% |
DBV Technologies S.A. | 89.4 Million EUR | 95.328% |
Genfit S.A. | 54.8 Million EUR | 92.378% |
GeNeuro SA | 14.35 Million EUR | 70.907% |
Innate Pharma S.A. | 64.57 Million EUR | 93.531% |
Inventiva S.A. | 120.18 Million EUR | 96.525% |
MaaT Pharma SA | 21.59 Million EUR | 80.66% |
MedinCell S.A. | 32.92 Million EUR | 87.312% |
Nanobiotix S.A. | 58.92 Million EUR | 92.912% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 82.293% |
Poxel S.A. | 28.76 Million EUR | 85.479% |
GenSight Biologics S.A. | 32.66 Million EUR | 87.211% |
Transgene SA | 31.23 Million EUR | 86.625% |
Valneva SE | 134.92 Million EUR | 96.904% |